TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Nebulised Gentamicin in Patients With Bronchiectasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bronchiectasis confirmed by HRCT of the chest~* Clinically stable (not requiring antibiotics for at least 4 weeks preceding the study start date)~* Aged 18-70~* Chronic sputum production \> 5 mls for the majority of days in 3 months before enrolment~* Chronically colonized (on at least 2 occasions in the preceding 12 months) whilst clinically stable~* At least two exacerbations in the past year~* Patients able to tolerate a nebulized gentamicin challenge~* FEV1 \> 30% predicted~* Smoking \< 20 pack year history and ex-smokers \>1 year.~Exclusion Criteria:~* Cystic fibrosis~* Emphysema on HRCT chest~* Thoracic surgery within the past 1 year~* Allergic bronchopulmonary aspergillosis~* Poorly controlled asthma ( \> 20% diurnal variation in peak expiratory flows despite treatment)~* Unstable angina or uncontrolled congestive cardiac failure~* Active malignancy~* Pregnancy or breast feeding~* Creatinine clearance \< 30 mls/minute~* Vestibular instability~* Previous documented intolerance to aminoglycosides

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Nebulised Gentamicin
- 2 (Type: PLACEBO_COMPARATOR): Nebulised 0.9% Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female 18 y/o and older~2. Female patients must be practicing an effective method of birth control~3. Biopsy-proven AL-amyloidosis~4. Must have been previously treated (failed at least 1 previous treatment) and in the opinion of the physician, patient requires further treatment~Exclusion Criteria:~1. Hypersensitivity to boron or mannitol~2. Prior treatment with VELCADE~3. Patient requires other concomitant chemotherapy, radiotherapy or ancillary therapy considered investigational~4. Uncontrolled infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): VELCADE

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram (ECG), and clinical laboratory determinations~* Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive~* Ages 18 to 45, inclusive~Exclusion Criteria:~* Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population~* Major surgical procedure within 4 weeks prior to randomization~* Positive serology test for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)~* Clinically significant history or presence of any of the following conditions: heart, liver, or kidney disease, neurologic or psychiatric disease~* History of gastrointestinal disease within the past 3 months~* Any clinically significant medical condition that could potentially affect your participation in the study and/or personal well-being, as judged by the investigator~* Donated blood or blood products to a blood bank, blood transfusion or participated in a clinical study (except a screening visit) requiring withdrawal of blood within 4 weeks prior to randomization~* Unable to tolerate oral and/or intravenous (IV) medications~* Unable to tolerate the puncturing of veins for drawing of blood~* Known allergy or hypersensitivity to any component of the study medication~* History of any significant drug allergies (such as anaphylaxis or hepatotoxicity)~* Used any prescription drugs or over the counter products to control acid (for example, Prevacid, Mylanta or Rolaids) within 4 weeks prior to randomization~* Used any other drugs including over the counter medications and herbal preparations within 1 week prior to randomization~* Taken any investigational drug or placebo (inactive drug) within 4 weeks prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 5 mg saxagliptin + a single 500 mg metformin XR tablet (Type: EXPERIMENTAL): None
- FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fed) (Type: EXPERIMENTAL): under fed state
- FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fasting) (Type: EXPERIMENTAL): under fasted state

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be 6 months of age or older, and in good general health;~* Have a written informed consent form signed by subject or a parent or legal guardian and an assent form as required;~* Have between 3 and 70 treatable MC at Baseline;~* Female subjects age 9 and above must have a negative UPT at Baseline;~* Female subjects age 9 and above must agree to practice a medically acceptable form of birth control during the study and for 30 days after Week 12/ET1;~* Be willing and able to follow study instructions and likely to complete all study requirements.~Exclusion Criteria:~* Have strongly suggested sexually transmitted MC and do not agree to refrain from sexual activities throughout the study period.~* Are immunosuppressed, have immunodeficiency disorder, or are on immunosuppressive treatment;~* Have significant injury on and/or surrounding MC that may impact ability to treat and count lesions;~* Have received treatment with topical calcineurin inhibitors or steroids on MC or within 2 cm of MC lesions within 14 days prior to Baseline;~* Have received treatment for MC during the 14 days prior to Baseline with podophyllotoxin, imiquimod, cantharidin, sinecatechins, topical retinoids, oral or topical zinc, or other homeopathic or over the counter (OTC) products including, but not limited to, ZymaDerm and tea tree oil, cimetidine and other histamine H2 receptor antagonists (including Zantac);~* Have received surgical procedures related to MC (cryotherapy, curettage, other) within 14 days prior to Baseline;~* Have MC only in periocular area;~* Female subjects who are pregnant, planning a pregnancy or breastfeeding;~* Have known hypersensitivity to any ingredients of SB206 or Vehicle Gel including excipients;~* Have participated in a previous study with a berdazimer sodium product (SB204, SB206, SB208, SB414);~* Have more than 1 family member currently participating in a study with a berdazimer sodium product (SB204, SB206, SB208, SB414).~* Have participated in any other trial of an interventional investigational drug or device within 14 days or concurrent participation in another interventional research study.~* History or presence of clinically significant medical, psychiatric, or emotional condition that, in opinion of the investigator, would compromise the safety of the subject or the quality of the data.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SB206 12% (Type: EXPERIMENTAL): SB206 12% topically once daily
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Placebo topically once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who have completed TAK-385/CCT-101 study~Exclusion Criteria:~1. Participants who had an adverse event in TAK-385/CCT-101 study which makes continued administration of the study drug difficult~2. Participants who became unable to comply with the protocol due to onset of a new disease, symptom, finding, or aggravation of clinical laboratory findings~3. Participants in whom investigator deems that the study drug shows no efficacy based on the level of pain, menstruation status, and the status of analgesic drug intake in TAK-385/CCT-101 study, or that study continuation represents an unacceptable risk~4. Participants in whom investigator deems that study continuation is difficult due to the occurrence of low estrogen symptoms in TAK-385/CCT-101 study which were attributed to the pharmacological effects of the study drug taking into account the level and frequency of the adverse events etc. as well as the risk-benefit of participants.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- TAK-385 10 mg QD (Type: EXPERIMENTAL): None
- TAK-385 20 mg QD (Type: EXPERIMENTAL): None
- TAK-385 40 mg QD (Type: EXPERIMENTAL): None
- Leuplin (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-dose Vitamin D Supplementation in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants with gestational age 24 to 32 weeks who achieved at least 75% of total nutrition by enteral feedings in postnatal 2 weeks~Exclusion Criteria:~* perinatal asphyxia,~* major congenital or chromosomal anomalies,~* those with no expectation of survival in first 2 weeks~* those that total parenteral nutrition was not ceased by the first 2 weeks

- Gender: ALL
- Minimum Age: 24 Weeks
- Maximum Age: 32 Weeks
- Healthy Volunteers: f

Study Arms:
- Devit-3 Oral Drop 400 IU (Type: OTHER): supplemented with oral Vitamin D 400 IU/day (Devit-3 Oral Drop, 50000 IU/15 ml, Deva Company, Turkey) started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
- Devit-3 Oral Drop 800 IU (Type: ACTIVE_COMPARATOR): Devit-3 Oral Drop 800 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
- Devit-3 Oral Drop 1000 IU (Type: ACTIVE_COMPARATOR): Devit-3 Oral Drop1000 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male or female over 20 years of age.~* Clinical diagnosis of advanced SMD.~* The visual acuity of the eye to receive the transplant will be no better than hand movement.~* The visual acuity of the eye that is not to receive the transplant will be no better than 24 (20/320) Early Treatment of Diabetic Retinopathy Study (ETDRS) letters.~Exclusion Criteria:~* History of malignancy.~* History of myocardial infarction in previous 12 months.~* History of diabetes mellitus.~* Any immunodeficiency.~* Any current immunosuppressive therapy other than intermittent or low dose cortico steroids.~* Serologic evidence of infection with Hepatitis B, Hepatitis C, or HIV.~* Current participation in any other clinical trial.~* Participation within previous 6 months in any clinical trial of a drug by ocular or systemic administration.~* Any other sight-threatening ocular disease.~* Any chronic ocular medications. Any history of retinal vascular disease (compromised blood-retinal barrier). Glaucoma. Uveitis or other intraocular inflammatory disease. Significant lens opacities or other media opacity. Ocular lens removal within previous 3 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MA09-hRPE administration (Type: EXPERIMENTAL): Biological: MA09-hRPE Cellular therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premature infants (\<37 weeks gestation)~* More than 1 significant Apnea q 8h (\> 20 sec or \< 20 sec with bradycardia or desaturation)~* Already treated with caffeine~Exclusion Criteria:~* Intubation~* congenital malformation~* symptomatic apnea

- Gender: ALL
- Minimum Age: 1 Week
- Maximum Age: 3 Months
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Treatment based on patient weight;
- 2 (Type: ACTIVE_COMPARATOR): Treatment based on a chart taking into account weight, age and gender

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sodium Thiosulfate Treatment of Vascular Calcification in ESRD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hemodialysis patient with thrice weekly treatments~* Coronary artery calcium score greater than 50~* Age greater than 18~* Compliant with hemodialysis treatments~* Informed consent~Exclusion Criteria:~* Allergy to sodium thiosulfate~* Pregnancy~* Incarceration~* Enrollment in another study~* Life expectancy less than 5 months~* Expectation of recovery of renal function~* Urine output of greater than 200 ml/day or contrast allergy will not receive intravenous contrast

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Treatment (Type: EXPERIMENTAL): This is the only arm and involves active treatment with sodium thiosulfate in those subjects with high coronary artery calcium scores.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Toujeo Versus NPH Self-titration Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetic suboptimally controlled on their previous antidiabetic treatment~  * 18 ≤ age ≤ 75~ * Stable dose of oral antidiabetic treatment for \> 8 weeks~ * The number of OADs that the patients used should be 3 or less~ * HbA1c level \> 7.0% and \< 10%~ * Fasting plasma glucose \> 8mmol/L and \<15mmol~ * BMI \< 40 kg/m2~ * Patient who is capable and willing to perform regular SMBG~ * Patient who is capable and willing for insulin injection~ * Confirmed written consent~ * Insulin naïve~Exclusion Criteria:~* Participation in a clinical trial with any investigational drug used with curative intent and within 30 days prior to study entry~* Patient known to have hypoglycaemia unawareness or recurrent major hypoglycaemia~* Any product containing prandial insulin~* Concomitant medication known to interface with glucose metabolism (such as systematic steroids)~* Change in dose of non-insulin anti-diabetic treatment or initiation of new anti-diabetic medications in the last 8 weeks prior to screening~* Patients treated with steroid or nonsteroidal anti-inflammatory drugs~* Patient who had experienced an acute concurrent illness during the 3-month period before the investigation~* Patient with hepatic disease and end-stage renal disease~* Patients unable to comply with follow-up visits~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Insulin glargine 300U/ml
- Control (Type: ACTIVE_COMPARATOR): Neutral Protamine Hagedorn insulin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study in RAD 001 Patients With Relapse AML

Study Design Characteristics:
- Allocation: None
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients from 18 to 65 years old~* AML in relapse more than 1 year after CR~* inform consent signed~Exclusion Criteria:~* age more than 65~* cardiac insufficiency~* renal insufficiency~* hepatic disease~* other type of AML~* blastic MCL~* HIV positive serology~* other malignancy~* pulmonary infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- RAD 001 (Type: EXPERIMENTAL): RAD 001 in day 1 and day 7 from 10 mg to 50 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunologic Response to FluMist vs. Flucelvax

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 4-21 years;~* has prior vaccination history available (which can be determined based either on medical record review or through state registry review);~* plans to receive the current seasonal influenza vaccination at one of the recruiting sites~Exclusion Criteria:~* unable or unwilling to completed required study activities, including informed consent, randomization to vaccine, and bloodwork;~* has already received influenza vaccine for the current season;~* has a known immunocompromising condition or is on an immunosuppressing medication (e.g., high dose steroids \>10 days);~* is known to be pregnant;~* has a history of severe allergy to eggs or to influenza vaccine or any of its components

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 21 Years
- Healthy Volunteers: t

Study Arms:
- FluMist live attenuated influenza vaccine (Type: ACTIVE_COMPARATOR): Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally
- Flucelvax inactivated influenza vaccine (Type: ACTIVE_COMPARATOR): Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benign Prostatic Hyperplasia and Ischemic Heart DIsease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* LUTS/BPH, with the total score by the IPSS more than or equal to 8;~* Functional class II-IV angina of effort;~* Non-ST segment depression postinfarction cardiosclerosis.~Exclusion Criteria:~* Presence of cystostomic drainage;~* Long-term LUTS/BPH therapy of prostatic hyperplasia (alpha-adrenoblockers, 5-alpha-reductase inhibitors and others) - for the groups of patients of conservative treatment of BPH;~* Patients after operative treatment of prostatic hyperplasia (TUR of prostatic hyperplasia, transvesical adenomectomy, etc.);~* Urinary bladder stones;~* Acute urinary retention;~* Changes on the ECG hampering its interpretation (complete left bundle branch block, cicatricial changes after endured myocardial infarction, permanent form of ciliary arrhythmia);~* Acute forms of ischaemic heart disease.

- Gender: MALE
- Minimum Age: 57 Years
- Maximum Age: 81 Years
- Healthy Volunteers: f

Study Arms:
- No intervention (Type: NO_INTERVENTION): It included the patients in whom during urination certain changes in HM were registered. The Group 1 patients' age varied from 63 to 79 years (mean 68.6±4.94 years). Nearly all except two patients (cardiac background of these patients did not require medical or surgical correction) from this group received cardiotropic therapy which did not change during one-month follow-up.
- Tamsulosin (Type: ACTIVE_COMPARATOR): This group enrolled 28 patients in whom primary HM detected certain alterations (VE, SVE, ST segment depression) which did not coincide with the act of urination. The age of patients was from 57 to 81 years (mean 71.3±1.1 years). In order to improve impaired urination were also received Tamsulosin at a dose of 0.4 mg once daily (in the morning) for the whole period of follow up and treatment. Tamsulosin Oral Capsule.
- TURP (Type: ACTIVE_COMPARATOR): This group was composed of patients for whom after examination for symptoms of IHD and LUTS/BPH a decision was made on the necessity to perform operative treatment of BPH. TURP operation was indicated due to pronounced urination disorders which were most important amongst the patient's complaints. The patients' age varied from 59 to 77 years (mean 67.5±2.1 years).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete